Hepatosplenic γδ T‐cell lymphoma in a 10‐year‐old boy successfully treated with hematopoietic stem cell transplantation

Gassas, Adam; Kirby, Melanie; Weitzman, Sheila; Ngan, Bo; Abla, Oussama; Doyle, John

doi:10.1002/ajh.10466

Cited by 27 publications

(19 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allogeneic transplant in young patients with aggressive disease (Table ), transplanted after first or second remission using different myeloablative conditioning regimens (often including total body irradiation), and with varied stem cells sources and immunosuppressant strategies, has occasionally been reported . All these patients developed a mild to moderate, acute or chronic graft vs. host disease that were successfully controlled; furthermore, they were all alive and relapse‐free at a follow‐up period between 12 and 58 months.…”

Section: Hepatosplenic Gamma‐delta T‐cell Lymphomamentioning

confidence: 99%

“…All these patients developed a mild to moderate, acute or chronic graft vs. host disease that were successfully controlled; furthermore, they were all alive and relapse‐free at a follow‐up period between 12 and 58 months. Overall results with allogeneic transplant are encouraging, even among paediatric patients , but treatment‐related mortality remains high; reduced intensity conditioning may be a good alternative .…”

Section: Hepatosplenic Gamma‐delta T‐cell Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Gamma‐delta t‐cell lymphomas

Foppoli

Ferreri

2014

European J of Haematology

View full text Add to dashboard Cite

Gamma-delta T-cell lymphomas are aggressive and rare diseases originating from gamma-delta lymphocytes. These cells, which naturally play a role in the innate, non-specific immune response, develop from thymic precursor in the bone marrow, lack the major histocompatibility complex restrictions and can be divided into two subpopulations: Vdelta1, mostly represented in the intestine, and Vdelta2, prevalently located in the skin, tonsils and lymph nodes. Chronic immunosuppression such as in solid organ transplanted subjects and prolonged antigenic exposure are probably the strongest risk factors for the triggering of lymphomagenesis. Two entities are recognised by the 2008 WHO Classification: hepatosplenic gamma-delta T-cell lymphoma (HSGDTL) and primary cutaneous gamma-delta T-cell lymphoma (PCGDTL). The former is more common among young males, presenting with B symptoms, splenomegaly and thrombocytopenia, usually with the absence of nodal involvement. Natural behaviour of HSGDTL is characterised by low response rates, poor treatment tolerability, common early progression of disease and disappointing survival figures. PCGDTL accounts for <1% of all primary cutaneous lymphomas, occurring in adults with relevant comorbidities. Cutaneous lesions may vary, but its clinical behaviour is usually aggressive and long-term survival is anecdotal. Available literature on gamma-delta T-cell lymphomas is fractioned, mostly consisting of case reports or small cumulative series. Therefore, clinical suspicion and diagnosis are usually delayed, and therapeutic management remains to be established. This review critically analyses available evidence on diagnosis, staging and behaviour of gamma-delta T-cell lymphomas, provides recommendations for therapeutic management in routine practice and discusses relevant unmet clinical needs for future studies.

show abstract

Section: Hepatosplenic Gamma‐delta T‐cell Lymphomamentioning

confidence: 99%

Section: Hepatosplenic Gamma‐delta T‐cell Lymphomamentioning

confidence: 99%

Gamma‐delta t‐cell lymphomas

Foppoli

Ferreri

2014

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…There are few reviews of the paediatric experience with HSTCL (Garcia‐Sanchez et al , ; Rossbach et al , ; Gassas et al , ; Domm et al , ; Moleti et al , ; Rosh et al , ); but individual case reports and small case series mirror the poor outcomes reported in adults. Successfully treated children have received chemotherapy alone (Moleti et al , ) and some received subsequent HSCT (Domm et al , ) but the optimal therapeutic approach to the treatment of HSTCL in children remains in question.…”

Section: Mature T‐cell Neoplasmsmentioning

confidence: 99%

Uncommon non‐Hodgkin lymphomas of childhood: pathological diagnosis, clinical features and treatment approaches

Sandlund

Perkins

2015

Br J Haematol

View full text Add to dashboard Cite

SummaryWe provide a review of the pathological and clinical features for uncommon B-cell and T-cell lymphomas of childhood with a specific focus on advances in treatment approaches and outcomes. There is clearly a need for prospective investigation of both the clinical and biological features of the uncommon non-Hodgkin lymphoma subtypes in childhood. These results should lead to more uniform and more effective treatment approaches.

show abstract

“…5 Although reported experiences with allogeneic transplantation are limited, demonstration of a graftversus-lymphoma effect would offer potentially curative alternative for patients with HSgdTCL. 4,[6][7][8][9] Thus far, at least three cases of HSgdTCL treated with allogeneic HSCT have been reported: a 23-year-old male, treated with TBI and high-dose etoposide followed by BMT from an HLAmatched sibling in the first remission; 8 a 10-year-old male, treated with CY/TBI followed by matched unrelated HSCT in the second remission; 7 a 25-year-old woman, treated with TBI/thiotepa/CY followed by unrelated-cord blood transplantation to residual disease after autologous PBSC transplantation. 9 All these patients developed mild to moderate acute or chronic GVHDs, which were successfully controlled.…”

mentioning

confidence: 99%